Primary Care Diabetes
Volume 4, Issue 2 , Pages 105-112 , July 2010

Obesity and diabetes: the links and common approaches

Received 13 May 2009 ,Revised 5 April 2010 ,Accepted 9 April 2010.

References 

  1. Wannamethee SG, Shaper AG. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care. 1999;22:1266–1272
  2. Counterweight data, unpublished, Presented at Hazardous Waist; Men's Health Forum Conference, Savoy Place, London, 13/6/05.
  3. Currie C, Peters J, Tynan A, Evans M, Heine R, Bracco O, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375(February (9713)):481–489
  4. D. Adler, The Life and Cuisine of Elvis Presley.
  5. Reaven G. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  6. An Interview with Gerald Reaven: Syndrome X: The Risks of Insulin Resistance, http://www.cacr.ca/information_for_public/archived_issues/2000s/0009Reaven.pdf (accessed 3.4.10).
  7. Rationale for new IDF worldwide definition of metabolic syndrome, http://www.idf.org/webdata/docs/Metabolic_syndrome_rationale.pdf (accessed 3.4.10).
  8. http://www.idf.org/webdata/docs/MetS_def_update2006.pdf (accessed 3.4.10).
  9. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N, et al. Hypertriglyceridemic waist, a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?. Circulation. 2000;102:179–184
  10. Christou NV, Sampalis JS, Liberman M, et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann. Surg. 2004;240(3):416–424
  11. Keating CL, Dixon JB, Moodie ML, et al. Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modelled lifetime analysis. Diabetes Care. 2009;
  12. Adams T, Richard MPH, Gres E, Smith SC, Halverson RC, Simper S, et al. Long-term mortality after gastric bypass surgery. NEJM. 2007;357:753–761
  13. Sjöström L, Narbro K, Sjöström CD, Karasno K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. NEJM. 2007;357:741–752
  14. Sjöström L, Lindroos A, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. NEJM. 2004;351:2683–2693
  15. Eric Yen C-L, et al. Deficiency of the intestinal enzyme acyl coa:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding. Nat. Med. 2009;(advance online publication)
  16. Deitel M. From bariatric to metabolic surgery in non-obese subjects: time for some caution. Arq. Bras. Endocrinol. Metab. 2009;53(no. 2):
  17. DePaula AL, Macedo CA, Rassi N, Machado CA, Schraibman , Silva LQ, et al. Laparoscopic treatment of type 2 diabetes mellitus for patients with body mass index less than 35. Surg. Endosc. 2008;22(3):706–716
  18. Ramos AC, Galvao MP, de Souza YM, Galvao M, Murakami AH, Silva AC, et al. Laparoscopic duodenal-jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI>30kg/m2 (LBMI). Obes. Surg. 2008;(Epub ahead of print)
  19. Dixon JB, O’Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes. A randomized control trial. JAMA. 2008;299(3):316–323
  20. Omana JJ, Nguyen SQ, Herron D, Kini S. Comparison of comorbidity resolution and improvement between laparoscopic sleeve gastrectomy and laparoscopic adjustable gastric banding. Surg. Endosc. 2010;(Epub ahead of print)
  21. Schouten R, Rijs CS, Bouvy ND, Hameeteman W, Koek GH, Janssen IM, et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann. Surg. 2010;251(February (2)):236–243
  22. Gersin KS, Rothstein RI, Rosenthal RJ, Stefanidis D, Deal SE, Kuwada TS, et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest. Endosc. 2010;(Epub ahead of print)
  23. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A . The SERENADE trial: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight and lipid profile in drug-naïve type 2 diabetes. Diabetes Care. 2008;(Published online before print)
  24. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004;27:155–161
  25. Sjöström L. Analysis of the XENDOS study (Xenical in the prevention of diabetes in obese subjects). Endocr. Pract. 2006;12(January–February (Suppl. 1)):31–33
  26. Berne C. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. Diabetic Med. 2004;22:612–618
  27. Wirth A. Reduction of body weight and co-morbidities by orlistat: the XXL – primary health care trial. Diabetes Obes. Metab. 2005;7(January (1)):21–27
  28. Bull E. Obesity; orlistat. Drugs Context. 2004;1(6):193–232
  29. James WPT, et al. Lancet. 2000;356:2119–2125
  30. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW . Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;(online publication). N.B. Erratum on sibutramine issued 21.11.09
  31. Haslam D. Sibutramine: gone but not forgotten. Pract. Diabetes Int. 2010;27(No 3):96–97
  32. http://www.idf.org/webdata/docs/GGT2D%2001%20Screening%20and%20diagnosis.pdf (accessed 4.4.10).
  33. Mayor S. Quarter of people with diabetes in England are undiagnosed. BMJ. 2005;331(7518):656
  34. National Collaborating Centre for Chronic Conditions . Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London: Royal College of Physicians; 2008;
  35. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. 2007;28(1):88–136
  36. Joint British Societies . JBS2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(Suppl. v):v1–v52
  37. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
  38. National Health Service . National Clinical Audit Support Programme (Diabetes). 2009;http://www.ic.nhs.uk/services/national-clinical-audit-support-programme ncasp/diabetes/analysis (accessed 10.02.09)
  39. Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929–940
  40. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008;359(15):1577–1589
  41. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853
  42. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann. Intern. Med. 1996;124(1 Pt 2):136–145
  43. ADVANCE Collaborative Group . N. Engl. J. Med. 2008;358:2560–2572
  44. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008;358(24):2560–2572
  45. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009;360(2):129–139
  46. UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865
  47. Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care. 1996;19(9):920–926
  48. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008;358(24):2545–2559
  49. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Poole CD Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375(9713):481–489
  50. W. Duckworth, Glycemic control and cardiovascular outcomes—the VA diabetes trial, American Diabetes Association 68th Scientific Sessions: VA Diabetes Trial Symposium, Presented 8 June 2008, Webcast available at http://www.diabetesconnect.org/storetemplate/Webcast_list.aspx?ses=874 (accessed 4.03.09), 2008.
  51. Bonds D, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909
  52. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705
  53. Sitagliptin Study 020 Group . Diabetes Care. 2006;29:2638–2643
  54. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr. Med. Res. Opin. 2008;24(February (2)):537–550
  55. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30(4):890–895
  56. Del Prato S. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes. Int. J. Clin. Pract. Suppl. 2007;August (154):38–48
  57. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin. Ther. 2007;29(1):139–153
  58. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90
  59. J. Jendle, M.A. Nauck, D. Matthews D., et al., The reduction of body weight with liraglutide, a once-daily human GLP-1 analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat, Presented at the 44th European Association for the Study of Diabetes Annual Meeting, Rome, Italy, 7–11 September, 2008.

PII: S1751-9918(10)00049-5

doi: 10.1016/j.pcd.2010.04.002

Primary Care Diabetes
Volume 4, Issue 2 , Pages 105-112 , July 2010

Article Tools